Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer

Mehdi Bouhaddou(QB3), Jennifer R. Grandis(University of California, San Francisco), Neil E. Bhola(University of California, San Francisco), Rex H. Lee, Adam B. Olshen(University of California, San Francisco), Scott Vandenberg(The University of Texas MD Anderson Cancer Center), Nevan J. Krogan(QB3), Aaron Hechmer(UCSF Helen Diller Family Comprehensive Cancer Center), Stephen B. Keysar(University of Colorado Denver), Umamaheswar Duvvuri(City University of New York), Daniel E. Johnson(UCSF Helen Diller Family Comprehensive Cancer Center), Ritu Roy(University of California, San Francisco), Jennifer Bolen(UCSF Helen Diller Family Comprehensive Cancer Center), Mohammad Naser(University of California, San Francisco), Rachel A. O’Keefe(University of California, San Francisco), Danielle L. Swaney(Gladstone Institutes), Hua Li, Tian Ran Zhu(Xi'an Honghui Hospital), Kelechi Nwachuku, Antonio Jimeno(The Medical Center of Aurora), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
JCI Insight
September 21, 2021
Cited by 19


Related Papers